Interleukin 5, Recombinant, Human (IL-5, BCDF-alpha, Eosinophil Differentiation Factor, EDF)

Recombinant Human IL-5 is a dimeric, non-glycosylated polypeptide chain containing 132 amino acids and having a molecular mass of 26522.84 Dalton. \n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Met-Ile-Pro-Thr-Glu. \n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis. \n\nBiological Activity:\nrHuIL-5 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of the proliferation of TF-1 cells was found to be less then 0.15ng/ml, corresponding to a Specific Activity of 6 x 10e6 IU/mg. \n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of rHuIL-5. \n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n1. UV spectroscopy at 280 nm using the absorbency value of 0.625 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). \n2. Analysis by RP-HPLC, using a standard solution of IL-5 as a Reference Standard. \n\nReconstitution:\nReconstitute the lyophilized rHuIL-5 in sterile ddH2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. \n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8427-01A

Size

2ug

Form

Supplied as a lyophilized powder. No additives.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Development and validation of a kinetic assay for analysis of anti-human interleukin-5 monoclonal antibody (SCH 55700) and human interleukin-5 interactions using surface plasmon resonance. DiGiacomo RA, Xie L, Indelicato SR, Anal Biochem 2004 Apr 15;327(2):165-75 2. Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. Ishino T, Pasut G, Chaiken I, J Biol Chem 2004 Mar 5;279(10):9547-56 3. Sequence-specific NMR resonance assignments for human interleukin-5. Feng H, Banville DL, J Biomol NMR 2002 Aug;23(4):329-30 4. Specific activation of human interleukin-5 depends on de novo synthesis of an AP-1 complex. Schwenger GT, Kok CC, Thomas MA, J Biol Chem 2002 Dec 6;277(49):47022-7 5. GATA-3 has dual regulatory functions in human interleukin-5 transcription. Schwenger GT, Fournier R, Mordvinov VA, J Biol Chem 2001 Dec 21;276(51):48502-9 6. Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells. Karras JG, McKay RA, Dean NM, Antisense Nucleic Acid Drug Dev 2000 Oct;10(5):347-57.